Literature DB >> 20504695

[(3)H]XAC (xanthine amine congener) is a radioligand for A(2)-adenosine receptors in rabbit striatum.

X D Ji1, G L Stiles, K A Jacobson.   

Abstract

The intrinsic affinity of 8-phenylxanthine analogs at striatal A(2)-adenosine receptors is highly species dependent. [(3)H]XAC (8-[2-aminoethyl[amino[carbonyl[methyl[oxyphenyl]]]]]-1,3-dipropylxanthine), although A(1)-selective in the rat brain, binds to A(2) receptors in rabbit striatal membranes with sufficiently high affinity to serve as a radioligand. In the presence of 50 nM CPX (8-cyclopentyl-1,3-dipropylxanthine), an A(1)-selective antagonist added to eliminate binding to A(1) receptors, [(3)H]XAC exhibits saturable, specific binding (70% of total) to A(2) sites with a K(d) of 3.8 nM and a B(max) of 1.23 pmol/mg protein. At 24 degrees C, the association and dissociation rate constants were 0.13 min(?1) nM(?1) and 0.36 min(?1), respectively. Binding was performed for 1 h, with non-specific binding defined in the presence of 100 ?M NECA (N-ethylcarboxamidoadenosine). The potency order for antagonists against 1 nM [(3)H]XAC at rabbit A(2)-receptors was XAC ? N(?)-Me-XAC ? CPX = XCC > 1,3-dipropyl-8-p-sulfophenylxanthine > PSPT. The relative potency order for agonists was CGS ? NECA > APEC [= 2-(aminoethylaminocarbonyl-ethylphenylethylamino)-NECA] > PAPA-APEC > ADAC > R-PIA (N(6)-phenylisopropyladenosine) > S-PIA. The ability to characterize central A(2)-adenosine receptors using an antagonist ligand that is chemically functionalized offers the possibility to design affinity labeling probes for this receptor subtype in the brain, similar to those antagonist probes already developed for A(1)-receptors. The results also suggest that affinity columns containing chemically immobilized XAC may be used for isolating central A(2)-adenosine receptors from rabbit striatum.

Entities:  

Year:  1991        PMID: 20504695      PMCID: PMC4827159          DOI: 10.1016/0197-0186(91)90187-i

Source DB:  PubMed          Journal:  Neurochem Int        ISSN: 0197-0186            Impact factor:   3.921


  22 in total

Review 1.  How does adenosine inhibit transmitter release?

Authors:  B B Fredholm; T V Dunwiddie
Journal:  Trends Pharmacol Sci       Date:  1988-04       Impact factor: 14.819

2.  A [3H]amine congener of 1,3-dipropyl-8-phenylxanthine. A new radioligand for A2 adenosine receptors of human platelets.

Authors:  D Ukena; K A Jacobson; K L Kirk; J W Daly
Journal:  FEBS Lett       Date:  1986-04-21       Impact factor: 4.124

3.  Characterization of the A2 adenosine receptor labeled by [3H]NECA in rat striatal membranes.

Authors:  R F Bruns; G H Lu; T A Pugsley
Journal:  Mol Pharmacol       Date:  1986-04       Impact factor: 4.436

4.  Agonist derived molecular probes for A2 adenosine receptors.

Authors:  K A Jacobson; L K Pannell; X D Ji; M F Jarvis; M Williams; A J Hutchison; W W Barrington; G L Stiles
Journal:  J Mol Recognit       Date:  1989-12       Impact factor: 2.137

5.  Purification of A1 adenosine receptor from rat brain membranes.

Authors:  H Nakata
Journal:  J Biol Chem       Date:  1989-10-05       Impact factor: 5.157

6.  Effects of 8-phenyl and 8-cycloalkyl substituents on the activity of mono-, di-, and trisubstituted alkylxanthines with substitution at the 1-, 3-, and 7-positions.

Authors:  M T Shamim; D Ukena; W L Padgett; J W Daly
Journal:  J Med Chem       Date:  1989-06       Impact factor: 7.446

7.  Measurement of protein using bicinchoninic acid.

Authors:  P K Smith; R I Krohn; G T Hermanson; A K Mallia; F H Gartner; M D Provenzano; E K Fujimoto; N M Goeke; B J Olson; D C Klenk
Journal:  Anal Biochem       Date:  1985-10       Impact factor: 3.365

8.  CGS 21680C, an A2 selective adenosine receptor agonist with preferential hypotensive activity.

Authors:  A J Hutchison; R L Webb; H H Oei; G R Ghai; M B Zimmerman; M Williams
Journal:  J Pharmacol Exp Ther       Date:  1989-10       Impact factor: 4.030

9.  Species differences in structure-activity relationships of adenosine agonists and xanthine antagonists at brain A1 adenosine receptors.

Authors:  D Ukena; K A Jacobson; W L Padgett; C Ayala; M T Shamim; K L Kirk; R O Olsson; J W Daly
Journal:  FEBS Lett       Date:  1986-12-01       Impact factor: 4.124

10.  Electrophilic derivatives of purines as irreversible inhibitors of A1 adenosine receptors.

Authors:  K A Jacobson; S Barone; U Kammula; G L Stiles
Journal:  J Med Chem       Date:  1989-05       Impact factor: 7.446

View more
  7 in total

Review 1.  Xanthines as adenosine receptor antagonists.

Authors:  Christa E Müller; Kenneth A Jacobson
Journal:  Handb Exp Pharmacol       Date:  2011

2.  Chemical modification and irreversible inhibition of striatal A2a adenosine receptors.

Authors:  K A Jacobson; G L Stiles; X D Ji
Journal:  Mol Pharmacol       Date:  1992-07       Impact factor: 4.436

3.  Identification of a novel high affinity adenosine binding protein from bovine striatum.

Authors:  A Lorenzen; S Grün; H Vogt; U Schwabe
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-07       Impact factor: 3.000

4.  Apparent heterogeneity of cardiac A1 adenosine receptors as revealed by radioligand binding experiments on N-ethylmaleimide-treated membranes.

Authors:  E Leung; K A Jacobson; R D Green
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-12       Impact factor: 3.000

5.  Solubilized rabbit striatal A2a-adenosine receptors: stability and antagonist binding.

Authors:  X D Ji; K A Jacobson
Journal:  Arch Biochem Biophys       Date:  1993-09       Impact factor: 4.013

6.  A1 adenosine receptors can occur manifesting two kinetic components of 8-cyclopentyl-1,3-[3H]dipropylxanthine ([3H]DPCPX) binding.

Authors:  V Casadó; J Mallol; R Franco; C Lluis; E I Canela
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-05       Impact factor: 3.000

7.  Characterization of human striatal A2-adenosine receptors using radioligand binding and photoaffinity labeling.

Authors:  X D Ji; G L Stiles; P J van Galen; K A Jacobson
Journal:  J Recept Res       Date:  1992
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.